Results 181 to 190 of about 157,909 (342)
Clinical Interpretation of Platelet Activation Marker sCLEC‐2 in Antiphospholipid Syndrome
Soluble C‐type lectin‐like receptor 2 (sCLEC‐2), a marker of platelet activation, was evaluated in patients with antiphospholipid syndrome (APS). Plasma sCLEC‐2 levels and the sCLEC‐2/D‐dimer ratio were significantly elevated in APS compared with other collagen diseases and healthy controls.
Risa Kaneshige +3 more
wiley +1 more source
ABSTRACT Background As solid organ transplantation becomes more prevalent, more patients are living on long‐term immunosuppression, greatly increasing the risk of cutaneous squamous cell carcinoma (cSCC). Although significant improvements have been achieved in the treatment of cSCC, further studies are needed to identify the specific protein expression
William Murray +8 more
wiley +1 more source
Evaluation of the Proliferation Marker Ki-67 for Improved Risk Stratification of Prostate Cancer Patients Under Active Surveillance. [PDF]
Schütz V +10 more
europepmc +1 more source
Association of argyrophilic nucleolar organizing regions, Ki-67, and proliferating cell nuclear antigen scores with histologic grade and survival in dogs with soft tissue sarcomas: 60 cases (1996—2002) [PDF]
S. Ettinger +7 more
openalex +1 more source
ABSTRACT Triple‐negative breast cancer (TNBC) is characterized as an aggressive malignancy with limited therapeutic options. The circular RNA circ_0006174 has been implicated in oncogenic processes across various cancers; however, its specific role in the pathogenesis of TNBC remains unclear.
Yong‐Zhe Tang +4 more
wiley +1 more source
Computer-aided techniques for Chromogenic Immunohistochemistry: Status and Directions [PDF]
Al-Kofahi +97 more
core +1 more source
Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik +3 more
wiley +1 more source

